
PhRMA brought me in to examine the acceleration of healthcare in what I described as an era of exponentiation.
The pharmaceutical industry was operating inside an extraordinary period of scientific change.
Genomics was accelerating.
Medical knowledge was expanding.
Personalized medicine was becoming more practical.
New therapeutic approaches were emerging.
And digital technologies were beginning to reshape research, treatment and the patient relationship.
Six themes framed the discussion:
- Genomic Acceleration
Genetic science was opening new therapeutic possibilities.
- Personalized Medicine
Treatments were becoming increasingly targeted to individual biology.
- Scientific Exponentiation
The pace of discovery itself was accelerating.
- Digital Health
Connected technologies were creating new information flows around patients and treatment.
- Knowledge Acceleration
Scientific insight was expanding faster than traditional knowledge systems could absorb it.
- Industry Transformation
Pharma strategy increasingly needed to respond to rapid change across science, data and healthcare delivery.
The core message was simple.
The future of pharma would not be shaped only by the next discovery.
It would be shaped by the fact that discovery was occurring faster.
Pharma was entering the era of exponentiation — where the rate of scientific progress becomes a strategic force in its own right.